-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The effectiveness of inflammatory bowel disease (IBD) often requires a colonoscopy to be clear, but colonoscopy is a more objective but more expensive and aggressive tool.
recently, measurements of drug valley levels (TL) and anti-drug antibodies in IBD patients using biologic agents have been widely used to assess whether patients receive drug treatment for loss of response (LOR) and primary non-reaction (PNR).
But such monitoring is also very expensive, and inflammatory fecal markers, especially fecal lactofitin (FL) and fecal calcium (FC), seem to be accurate indicators of inflammation of the intestinal mucous membranes.
previous studies have shown that elevated FC levels in patients with IBD are associated with increased inflammatory activity during treatment.
levels of lactotinin (FL) in feces may reflect inflammatory changes in drug-based ulcerative colitis and Crohn's disease in a timely manner and can be used to assess loss of response to biological agents (LOR).
, this study aims to explore whether fecal ferrin levels can predict the effectiveness of inflammatory bowel disease.
researchers conducted retrospective analysis of 61 patients treated at the medical center who were treated with adamu monoantigen, inflixi monoantigen, or Vidoju monoantigen, for a follow-up period of 6 to 24 months.
all patients are in clinical remission or are experiencing a possible LOR period.
a statistical analysis to assess whether fecal lactoxin levels can predict the therapeutic effect of inflammatory bowel disease.
Of the 31 patients in the disease remission period, 71% showed a slow increase in FL during the treatment interval (R2 s 0.769; P slt;0.001), the drug level was detected to decrease and inflammation increased.
in the rest of the patients, no FL increase was detected throughout the treatment interval due to a stronger inhibition of inflammation.
for patients who experienced LOR, FL levels measured 1 to 3 days after treatment increased compared to pre-drug levels.
normalized 3-month standardized clinical scores (0.58±0.21 vs. 0.13±0.09 for patients in either state after FL-based treatment; P .lt;0.001), and FL levels have dropped by as much as 99%.
this study confirms that FL levels can reflect changes in mucous membrane inflammation caused by drugs in a timely manner, allowing for a rapid assessment of treatment responses in patients with ulcerative colitis and Crohn's disease.
in patients suspected of having LOR, FL levels before and after infusion/injection accurately distinguish between responders, some responders and non-responders.